GERALDINE HENWOOD Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for GERALDINE HENWOOD.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of GERALDINE HENWOOD. GERALDINE HENWOOD is Director in ALKERMES INC ($ALKS) and Director in TETRAPHASE PHARMACEUTICALS INC ($TTPH) and Chief Executive Officer in Recro Pharma, Inc. ($REPH) and Director in Recro Pharma, Inc. ($REPH) and President and CEO in Recro Pharma, Inc. ($REPH) and President and CEO in Baudax Bio, Inc. ($BXRX).
Latest Insider Trading Transactions of GERALDINE HENWOOD
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ALKS, BXRX, REPH, TTPH
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 10 2021 | BXRX | Baudax Bio, Inc. | HENWOOD GERALDINE | President and CEO | Buy | P | 0.83 | 6,000 | 4,992 | 356,307 | 350.3 K to 356.3 K (+1.71 %) |
| Apr 22 2021 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | Director | Option Exercise | A | 1.71 | 38,012 | 65,001 | 38,012 | |
| Apr 22 2021 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | Director | Grant | A | 0.00 | 26,923 | 0 | 226,574 | 199.7 K to 226.6 K (+13.49 %) |
| Apr 15 2021 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | Director | Option Exercise | A | 2.93 | 20,000 | 58,600 | 20,000 | |
| Apr 15 2021 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | Director | Option Exercise | A | 2.93 | 20,000 | 58,600 | 20,000 | |
| Jan 20 2021 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | Director | Option Exercise | M | 0.00 | 5,000 | 0 | 0 | |
| Jan 20 2021 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | Director | Payment of Exercise | F | 3.03 | 6,816 | 20,652 | 199,651 | 206.5 K to 199.7 K (-3.30 %) |
| Jan 20 2021 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | Director | Buy | M | 0.00 | 5,000 | 0 | 206,467 | 201.5 K to 206.5 K (+2.48 %) |
| Dec 09 2020 | BXRX | Baudax Bio, Inc. | HENWOOD GERALDINE | President and CEO | Payment of Exercise | F | 1.14 | 71,283 | 81,263 | 284,872 | 356.2 K to 284.9 K (-20.01 %) |
| Dec 09 2020 | BXRX | Baudax Bio, Inc. | HENWOOD GERALDINE | President and CEO | Payment of Exercise | F | 1.14 | 11,732 | 13,374 | 356,155 | 367.9 K to 356.2 K (-3.19 %) |
| Dec 09 2020 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Payment of Exercise | F | 2.30 | 34,128 | 78,494 | 207,066 | 241.2 K to 207.1 K (-14.15 %) |
| Apr 20 2020 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Sell | S | 8.22 | 80,000 | 657,600 | 161,194 | 241.2 K to 161.2 K (-33.17 %) |
| Jan 29 2020 | BXRX | Baudax Bio, Inc. | HENWOOD GERALDINE | President and CEO | Payment of Exercise | F | 8.51 | 5,051 | 42,984 | 367,887 | 372.9 K to 367.9 K (-1.35 %) |
| Jan 29 2020 | BXRX | Baudax Bio, Inc. | HENWOOD GERALDINE | President and CEO | Buy | M | 0.00 | 19,070 | 0 | 372,938 | 353.9 K to 372.9 K (+5.39 %) |
| Jan 22 2020 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Option Exercise | M | 0.00 | 5,000 | 0 | 5,000 | |
| Jan 22 2020 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Payment of Exercise | F | 16.38 | 5,552 | 90,942 | 241,194 | 246.7 K to 241.2 K (-2.25 %) |
| Jan 22 2020 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Buy | M | 0.00 | 5,000 | 0 | 246,746 | 241.7 K to 246.7 K (+2.07 %) |
| Jan 03 2020 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Payment of Exercise | F | 17.53 | 4,945 | 86,686 | 241,746 | 246.7 K to 241.7 K (-2.00 %) |
| Dec 09 2019 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Grant | A | 0.00 | 93,550 | 0 | 246,691 | 153.1 K to 246.7 K (+61.09 %) |
| Dec 09 2019 | BXRX | Baudax Bio, Inc. | HENWOOD GERALDINE | President and CEO | Option Exercise | A | 6.33 | 183,673 | 1,162,650 | 183,673 | |
| Dec 09 2019 | BXRX | Baudax Bio, Inc. | HENWOOD GERALDINE | President and CEO | Grant | A | 0.00 | 128,571 | 0 | 353,868 | 225.3 K to 353.9 K (+57.07 %) |
| Dec 09 2019 | BXRX | Baudax Bio, Inc. | HENWOOD GERALDINE | President and CEO | Grant | A | 0.00 | 195,387 | 0 | 225,297 | 29.9 K to 225.3 K (+653.25 %) |
| Jun 11 2019 | TTPH | TETRAPHASE PHARMAC ... | HENWOOD GERALDINE | Director | Option Exercise | A | 0.77 | 16,500 | 12,705 | 16,500 | |
| May 15 2019 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Option Exercise | M | 2.47 | 123,500 | 305,045 | 0 | |
| May 15 2019 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Sell | S | 8.89 | 21,306 | 189,381 | 198,141 | 219.4 K to 198.1 K (-9.71 %) |
| May 15 2019 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Sell | S | 8.89 | 123,500 | 1,097,915 | 219,447 | 342.9 K to 219.4 K (-36.01 %) |
| May 15 2019 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Buy | M | 2.47 | 123,500 | 305,045 | 342,947 | 219.4 K to 342.9 K (+56.28 %) |
| Jan 23 2019 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Option Exercise | M | 0.00 | 5,000 | 0 | 10,000 | |
| Jan 23 2019 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Option Exercise | A | 7.99 | 171,184 | 1,367,760 | 171,184 | |
| Jan 23 2019 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Payment of Exercise | F | 7.99 | 1,425 | 11,386 | 214,384 | 215.8 K to 214.4 K (-0.66 %) |
| Jan 23 2019 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Buy | M | 0.00 | 5,000 | 0 | 215,809 | 210.8 K to 215.8 K (+2.37 %) |
| Jan 23 2019 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Grant | A | 0.00 | 35,801 | 0 | 210,809 | 175 K to 210.8 K (+20.46 %) |
| Jan 04 2019 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Payment of Exercise | F | 7.41 | 4,223 | 31,292 | 175,008 | 179.2 K to 175 K (-2.36 %) |
| Jan 04 2019 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Payment of Exercise | F | 7.41 | 4,223 | 31,292 | 175,008 | 179.2 K to 175 K (-2.36 %) |
| Jun 01 2018 | TTPH | TETRAPHASE PHARMAC ... | HENWOOD GERALDINE | Director | Option Exercise | A | 3.68 | 12,500 | 46,000 | 12,500 | |
| Jan 22 2018 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Option Exercise | M | 0.00 | 5,000 | 0 | 15,000 | |
| Jan 22 2018 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Payment of Exercise | F | 8.89 | 1,575 | 14,002 | 179,231 | 180.8 K to 179.2 K (-0.87 %) |
| Jan 22 2018 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Buy | M | 0.00 | 5,000 | 0 | 180,806 | 175.8 K to 180.8 K (+2.84 %) |
| Jan 04 2018 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Option Exercise | A | 9.04 | 100,000 | 904,000 | 100,000 | |
| Jan 04 2018 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Grant | A | 0.00 | 50,000 | 0 | 175,806 | 125.8 K to 175.8 K (+39.74 %) |
| Oct 02 2017 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Payment of Exercise | F | 9.04 | 9,794 | 88,538 | 125,806 | 135.6 K to 125.8 K (-7.22 %) |
| Oct 02 2017 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Buy | M | 0.00 | 31,100 | 0 | 135,600 | 104.5 K to 135.6 K (+29.76 %) |
| Jun 01 2017 | TTPH | TETRAPHASE PHARMAC ... | HENWOOD GERALDINE | Director | Option Exercise | A | 6.89 | 12,500 | 86,125 | 12,500 | |
| Jan 20 2017 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | Chief Executive Off ... | Option Exercise | A | 0.00 | 20,000 | 0 | 20,000 | |
| Jan 20 2017 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | Chief Executive Off ... | Option Exercise | A | 7.33 | 144,700 | 1,060,651 | 144,700 | |
| Dec 05 2016 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | Director | Option Exercise | A | 8.41 | 52,650 | 442,787 | 105,300 | |
| Nov 03 2016 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Option Exercise | A | 8.41 | 52,650 | 442,787 | 52,650 | |
| Jun 10 2016 | TTPH | TETRAPHASE PHARMAC ... | HENWOOD GERALDINE | Director | Option Exercise | A | 4.27 | 10,000 | 42,700 | 10,000 | |
| Dec 18 2015 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Option Exercise | A | 8.41 | 105,300 | 885,573 | 105,300 | |
| Jun 09 2015 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Buy | P | 9.56 | 550 | 5,258 | 104,500 | 104 K to 104.5 K (+0.53 %) |
| Jun 09 2015 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Buy | P | 8.83 | 3,950 | 34,879 | 103,950 | 100 K to 104 K (+3.95 %) |
| Apr 16 2015 | TTPH | TETRAPHASE PHARMAC ... | HENWOOD GERALDINE | Director | Option Exercise | A | 39.07 | 20,000 | 781,400 | 20,000 | |
| Oct 08 2009 | ALKS | ALKERMES INC | HENWOOD GERALDINE | Director | Option Exercise | A | 8.98 | 20,000 | 179,600 | 20,000 | |
| Oct 09 2008 | ALKS | ALKERMES INC | HENWOOD GERALDINE | Director | Option Exercise | A | 11.44 | 20,000 | 228,800 | 20,000 | |
| Oct 11 2007 | ALKS | ALKERMES INC | HENWOOD GERALDINE | Director | Option Exercise | A | 18.29 | 20,000 | 365,800 | 20,000 | |
| Sep 22 2006 | ALKS | ALKERMES INC | HENWOOD GERALDINE | Director | Option Exercise | A | 14.04 | 20,000 | 280,800 | 20,000 | |
| Sep 27 2005 | ALKS | ALKERMES INC | HENWOOD GERALDINE | Director | Option Exercise | A | 16.77 | 20,000 | 335,400 | 20,000 | |
| Sep 27 2004 | ALKS | ALKERMES INC | HENWOOD GERALDINE | Director | Option Exercise | A | 11.84 | 20,000 | 236,800 | 20,000 | |
| Sep 11 2003 | ALKS | ALKERMES INC | HENWOOD GERALDINE | Director | Option Exercise | A | 13.44 | 20,000 | 268,800 | 20,000 |
Page: 1